Zoll Medical Corp.‘s second-quarter sales could use some reviving.
The Chelmsford resuscitation devices and software maker posted a 7 percent revenue slide, reporting a 37 percent decline in sales to the North American hospital market and a $5 million hit from unfavorable foreign exchange rates.
Quarterly sales reached $92.7 million, down 7 percent compared with $99.2 million during the same period last year.
Net income plummeted to $1.8 million down 68.5 percent compared with $5.7 million.
CEO Richard Packer said the company’s strong pre-hospital and and international sales weren’t enough to offset the decline in the North American hospital market, as they did during the first quarter. Sales to that market fell to $17.5 million, compared to $27.9 million during the second quarter of 2009.
That slide included a nearly 33 percent decline in military sales, which dropped to $1.4 million, compared with $3.7 million for the same period last year.
Packer said the company expects “modest results” this year, as customers limit their capital expenditures to weather the down economy. On the upside, Zoll will add revenues from its $12 million acquisition of Alsius Corp. to boost its 2009 results, he said.
In a separate announcement, the company said its R series defibrillators were cleared for sale in China.